- Previous Close
33.81 - Open
34.00 - Bid 32.61 x --
- Ask 32.93 x --
- Day's Range
32.60 - 34.00 - 52 Week Range
30.00 - 78.48 - Volume
1,162 - Avg. Volume
4,879 - Market Cap (intraday)
302.107M - Beta (5Y Monthly) -0.31
- PE Ratio (TTM)
-- - EPS (TTM)
-8.40 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 19, 2022
- 1y Target Est
--
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and fine chemicals in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was founded in 2007 and is based in Hyderabad, India.
vineetlabs.co.inRecent News: VINEETLAB.BO
View MorePerformance Overview: VINEETLAB.BO
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VINEETLAB.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VINEETLAB.BO
View MoreValuation Measures
Market Cap
302.11M
Enterprise Value
691.41M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.31
Price/Book (mrq)
1.21
Enterprise Value/Revenue
0.71
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-7.83%
Return on Assets (ttm)
--
Return on Equity (ttm)
-25.85%
Revenue (ttm)
988.93M
Net Income Avi to Common (ttm)
-77.42M
Diluted EPS (ttm)
-8.40
Balance Sheet and Cash Flow
Total Cash (mrq)
10.08M
Total Debt/Equity (mrq)
159.49%
Levered Free Cash Flow (ttm)
--